Business Wire

Novaremed Announces Publication of Phase 1 and Phase 2a Study Data With NRD.E1 Demonstrating the Potential of This Investigational Non-opioid Pain Treatment

Share

Novaremed AG, a privately held clinical-stage biopharmaceutical company focused on innovative non-opioid treatment options for chronic pain management announces the simultaneous publication of data from three Phase 1 studies in Clinical Pharmacology in Drug Development and one Phase 2a, placebo-controlled, dose-finding, proof of concept study in European Journal of Pain with the Company’s lead investigational drug candidate NRD.E1, an innovative non-opioid therapy for painful diabetic peripheral neuropathy.

“We are delighted with the publication of our Phase 1 and Phase 2a studies which collectively demonstrate the drug candidate’s potential as an innovative non-opioid treatment option for patients with chronic pain,” said Eva Tiecke, PhD, Chief Scientific Officer and Head of R&D of Novaremed and lead author of both publications. “In the Phase 2a proof of concept study, the primary endpoint showed a clinically relevant placebo-corrected treatment effect in pain reductions at 40 and 150 mg/day of 0.82 Numerical Rating Scale points, p = 0.034 and 0.66, p= 0.061, respectively, though it narrowly missed the pre-specified value of p = 0.016 due to multiplicity. Overall, the study showed robust results given the consistent performance across multiple endpoints. Based on the data now published in peer-reviewed journals, we are encouraged about the potential of NRD.E1 to address the high unmet medical need for a non-opioid agent to treat chronic pain.”

In three Phase 1 studies NRD.E1 was well tolerated as single dose up to 1200 mg and repeated doses of 300 mg/day for five consecutive days. The studies revealed dose-dependent absorption, small increased exposure to NRD.E1 at peak when administered with food and no relevant accumulation after oral administration. The Phase 2a study was a randomized, double-blind, placebo-controlled, dose-finding, proof-of-concept study in 88 patients with PDPN. The study investigated NRD.E1 at 10, 40, or 150 mg/day or placebo over a 3-week treatment period. Primary, pre-specified secondary and post-hoc secondary endpoints analyses consistently demonstrate a clinically meaningful reduction in pain. NRD.E1 was safe and well tolerated.

References:

[1] Tiecke E., Rainisio M., Guentert T., Müller S., Hochman L., Kaplan E., Mangialaio S. (2022). First-in-human single-ascending-dose, multiple-dose and food interaction studies of NRD.E1, an innovative non-opioid therapy for painful diabetic peripheral neuropathy. Clinical Pharmacology in Drug Development (CPDD) (https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1103).

[2] Tiecke E., Rainisio M., Eisenberg E., Wainstein J., Kaplan E., Silverberg M., Hochman L., Mangialaio S. (2022) NRD.E1, an innovative non-opioid therapy for painful diabetic peripheral neuropathy – a randomized proof of concept study. European Journal of Pain (https://onlinelibrary.wiley.com/doi/10.1002/ejp.1989).

About NRD.E1 and the treatment of chronic pain
NRD.E1, an orally active small molecule with a novel mechanism of action and patent protection until 2040, is Novaremed's lead compound currently being developed to treat PDPN.

On the basis of the results now published, NRD.E1 was selected by the NIH as the only oral agent to be included in the NIH-HEAL (Help End Long-term Addiction) program. The NIH will sponsor and execute by the and conducted by EPPIC-Net (Early Phase Pain Investigation Clinical Network) a 12-week, double-blind, placebo-controlled Phase 2b study in patients with moderate to severe PDPN in the US. Novaremed has an open IND and received Fast Track Designation from the FDA for NRD.E1.

About Novaremed
Novaremed AG, a privately held clinical-stage biopharmaceutical company, is developing a pipeline of innovative medications for chronic pain management to address the high unmet medical need for better pain relief and as an alternative to opioids. Its lead product is NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action, has FDA Fast Track Designation and IND-approval to proceed with a Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy (PDPN). The earlier stage pipeline addressing chronic pain includes the development candidates MP-101 (early clinical development stage), and MP-103 (preclinical stage), targeting the unmet medical need of prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN). For more information: www.novaremed.com.

Read the full press release at www.novaremed.com or click here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mark Altmeyer, Executive Member of the Board
mark.altmeyer@novaremed.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China4.7.2022 14:30:00 EEST | Press release

A kick off ceremony was held at Gleneagles Hospital Hong Kong (Gleneagles or GHK) for initiating a clinical trial to assess the safety and immunogenicity of the SINOVAC’s Omicron-specific COVID-19 inactivated vaccine used as a booster shot in healthy adults, in anticipation of providing scientific evidence for future immunization strategy. This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220704005146/en/ [From right to left] Professor Ivan Hung Fan-ngai, Ru Chien & Helen Lieh Professor in Health Sciences Pedagogy, Clinical Professor and Chief of Infectious Diseases, Department of Medicine, School of Clinical Medicine, Assistant Dean (Admissions), LKS Faculty of Medicine of The University of Hong Kong; Dr Kenneth Tsang, CEO of Gleneagles Hospital Hong Kong; Ms. Cheryl Law, International

BearingPoint Appoints 19 New Partners Across Europe4.7.2022 10:58:00 EEST | Press release

Management and technology consultancy BearingPoint announced today that it has appointed 19 new Partners across Europe. 14 Partners have been internally promoted, and five Partners joined BearingPoint from outside the firm. The appointments underline the firm’s ongoing success and growth and the ambitions defined in its Strategy 2025: putting people in the center, outperforming the market every year, and being in the top three in chosen areas of expertise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220704005035/en/ Kiumars Hamidian, Managing Partner BearingPoint. (Photo: Business Wire) Kiumars Hamidian, Managing Partner BearingPoint, said: “It is a real pleasure that we were able to promote internally 14 new Partners to our Partner-led firm. All of them have reached this important milestone based on their exceptional abilities, deep industry expertise and outstanding commitment to serving our clients. In addition to our

VOOPOO Unveils 3 New Products, Telling Story of Its 8-year Entrepreneurship Journey in 30 Minutes4.7.2022 10:15:00 EEST | Press release

VOOPOO’s 2022 "More Than Infinity" virtual product launch was held on June 29, 2022, where VOOPOO took 30 minutes to review its brand story during the past 8 years since its founding, expounding the connection between the “infinity symbol” and the brand spirit and demonstrating its commitment to creating infinite new possibilities using technology in 3 chapters. Meanwhile, the event was highlighted by 3 POD products featuring VOOPOO’s most cutting-edge technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005586/en/ Infinite innovation: The new product launch, backed by atomization platforms and chip development, manifests VOOPOO’s R&D strength. (Graphic: Business Wire) A very important theme at the virtual event was telling the growth story of VOOPOO since its founding 8 years ago. Evolving from an atomization chip solution provider to today’s industry leader of open electronic atomization, VOOPOO has driven the

AGILA Pet Insurance becomes part of JAB Backed Pinnacle Pet Group, to create a Leading Pan-European Pet Insurance Platform4.7.2022 10:00:00 EEST | Press release

JAB Holding Company ("JAB") and WERTGARANTIE Group today announced a strategic partnership whereby JAB's European pet insurance platform, Pinnacle Pet Group ("PPG") will acquire 100% of the shares in AGILA Tierversicherung AG (“AGILA”), the German market leader in pet insurance, from the WERTGARANTIE Group. In return, the WERTGARANTIE Group will become an investor in PPG. The transaction is expected to close in Q4 2022, subject to customary closing conditions, including regulatory approvals. The parties have agreed not to disclose the financial details of the transaction. With JAB’s support, PPG will be built into a leading Pan-European platform for animal insurance through strategic investments and organic growth. The WERTGARANTIE Group will also continue to support PPG successful German activities as a relevant shareholder. AGILA will be an essential component of PPG's expansion. All employees at the Hanover headquarters will join the platform and will play a key role in PPG’s expans

Port Decarbonization: the First High-powered Hydrogen Barge for the Electrification of Ships at Berth4.7.2022 09:00:00 EEST | Press release

Hydrogène de France (“HDF Energy”) – Euronext Paris: HDF – and its partners of the ELEMANTA H2 project announce the signature of an MoU to deploy mobile solutions providing, from green or low-carbon hydrogen, cold ironing services complementing the electrical grid, for container ships, cruise ships or tankers. ELEMANTA H2 will also enable hydrogen bunkering to meet the refueling needs of future hydrogen ships. Maritime transport accounted for 13.5% of European total greenhouse gas emissions in 2018. In order to reach the European objective of reducing greenhouse gas emissions by 55% by 2030, the sector must accelerate its energy transition. ELEMANTA H2 aims to contribute to the decarbonization of port activities. The partners have identified the Port of Rouen and the Rubis Terminal location as a pioneer site because of its strategic position close to Paris. With the support of Normandie Energies and the port operator HAROPA, a demonstration barge will embed a high-power hydrogen fuel c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom